Attached files
file | filename |
---|---|
EX-32.1 - EXHIBIT 32.1 - KMG CHEMICALS INC | c09504exv32w1.htm |
EX-31.1 - EXHIBIT 31.1 - KMG CHEMICALS INC | c09504exv31w1.htm |
EX-32.2 - EXHIBIT 32.2 - KMG CHEMICALS INC | c09504exv32w2.htm |
EX-31.2 - EXHIBIT 31.2 - KMG CHEMICALS INC | c09504exv31w2.htm |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended October 31, 2010
or
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to .
Commission file number: 000-29278
KMG CHEMICALS, INC.
(Exact name of registrant as specified in its charter)
Texas | 75-2640529 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
9555 West Sam Houston Parkway South, Suite 600 | ||
Houston, Texas | 77099 | |
(Address of principal executive offices) | (Zip Code) |
(713) 600-3800
(Registrants telephone number, including area code)
(Registrants telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or
for such shorter period that the registrant was required to submit and post such files). Yes o No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):
Large accelerated filer o | Accelerated filer þ | Non-accelerated filer o (Do not check if a smaller reporting company) |
Smaller reporting company o |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act). Yes o No þ
As of December 7, 2010, there were 11,303,708 shares of the registrants common stock
outstanding.
TABLE OF CONTENTS
3 | ||||||||
3 | ||||||||
4 | ||||||||
5 | ||||||||
6 | ||||||||
14 | ||||||||
18 | ||||||||
19 | ||||||||
19 | ||||||||
20 | ||||||||
20 | ||||||||
20 | ||||||||
20 | ||||||||
20 | ||||||||
20 | ||||||||
21 | ||||||||
Exhibit 31.1 | ||||||||
Exhibit 31.2 | ||||||||
Exhibit 32.1 | ||||||||
Exhibit 32.2 |
2
Table of Contents
PART I FINANCIAL INFORMATION
ITEM 1. | FINANCIAL STATEMENTS |
KMG CHEMICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except for share and per share data)
October 31, | July 31, | |||||||
2010 | 2010 | |||||||
(Unaudited) | ||||||||
ASSETS |
||||||||
CURRENT ASSETS: |
||||||||
Cash and cash equivalents |
$ | 4,735 | $ | 4,728 | ||||
Accounts receivable: |
||||||||
Trade, net of allowances of $260 at October 31, 2010 and at July 31, 2010 |
28,484 | 30,214 | ||||||
Other |
3,444 | 2,864 | ||||||
Inventories, net |
41,153 | 39,102 | ||||||
Current deferred tax assets |
800 | 672 | ||||||
Prepaid expenses and other current assets |
1,305 | 1,882 | ||||||
Total current assets |
79,921 | 79,462 | ||||||
PROPERTY, PLANT AND EQUIPMENT, net |
69,815 | 68,645 | ||||||
DEFERRED TAX ASSETS |
874 | 606 | ||||||
GOODWILL |
3,778 | 3,778 | ||||||
INTANGIBLE ASSETS, net |
20,230 | 20,534 | ||||||
RESTRICTED CASH |
| 189 | ||||||
OTHER ASSETS, net |
3,047 | 2,807 | ||||||
TOTAL ASSETS |
$ | 177,665 | $ | 176,021 | ||||
LIABILITIES & STOCKHOLDERS EQUITY |
||||||||
CURRENT LIABILITIES: |
||||||||
Accounts payable |
$ | 22,456 | $ | 20,899 | ||||
Accrued liabilities |
6,394 | 7,147 | ||||||
Current deferred tax liabilities |
28 | 28 | ||||||
Current portion of long-term debt |
8,000 | 8,000 | ||||||
Total current liabilities |
36,878 | 36,074 | ||||||
LONG-TERM DEBT, net of current portion |
46,333 | 51,333 | ||||||
DEFERRED TAX LIABILITIES |
3,121 | 2,644 | ||||||
OTHER LONG-TERM LIABILITIES |
1,220 | 1,192 | ||||||
Total liabilities |
87,552 | 91,243 | ||||||
COMMITMENTS AND CONTINGENCIES |
||||||||
STOCKHOLDERS EQUITY |
||||||||
Preferred stock, $.01 par value, 10,000,000 shares authorized, none issued |
| | ||||||
Common stock, $.01 par value, 40,000,000 shares authorized, 11,303,708
shares issued and outstanding at October 31, 2010 and 11,229,487 shares
issued and outstanding at July 31, 2010 |
113 | 112 | ||||||
Additional paid-in capital |
24,885 | 24,319 | ||||||
Accumulated other comprehensive loss |
(1,857 | ) | (3,335 | ) | ||||
Retained earnings |
66,972 | 63,682 | ||||||
Total stockholders equity |
90,113 | 84,778 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY |
$ | 177,665 | $ | 176,021 | ||||
See notes
to condensed consolidated financial statements.
3
Table of Contents
KMG CHEMICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
(in thousands except for per share data)
Three Months Ended | ||||||||
October 31, | ||||||||
2010 | 2009 | |||||||
NET SALES |
$ | 62,104 | $ | 49,414 | ||||
COST OF SALES |
44,736 | 31,023 | ||||||
Gross Profit |
17,368 | 18,391 | ||||||
DISTRIBUTION EXPENSES |
6,372 | 5,021 | ||||||
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES |
5,436 | 5,420 | ||||||
Operating income |
5,560 | 7,950 | ||||||
OTHER INCOME (EXPENSE): |
||||||||
Interest income |
1 | 1 | ||||||
Interest expense |
(595 | ) | (557 | ) | ||||
Other, net |
51 | (28 | ) | |||||
Total other expense, net |
(543 | ) | (584 | ) | ||||
INCOME BEFORE INCOME TAXES |
5,017 | 7,366 | ||||||
Provision for income taxes |
(1,501 | ) | (2,746 | ) | ||||
NET INCOME |
$ | 3,516 | $ | 4,620 | ||||
EARNINGS PER SHARE: |
||||||||
Basic |
$ | 0.31 | $ | 0.41 | ||||
Diluted |
$ | 0.31 | $ | 0.41 | ||||
WEIGHTED AVERAGE SHARES OUTSTANDING: |
||||||||
Basic |
11,299 | 11,144 | ||||||
Diluted |
11,460 | 11,375 |
See notes
to condensed consolidated financial statements.
4
Table of Contents
KMG CHEMICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in thousands)
Three Months Ended | ||||||||
October 31, | ||||||||
2010 | 2009 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||
Net income |
$ | 3,516 | $ | 4,620 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Depreciation and amortization |
2,240 | 1,379 | ||||||
Amortization of loan costs included in interest expense |
27 | 22 | ||||||
Stock-based compensation expense |
181 | 86 | ||||||
Bad debt expense |
| 170 | ||||||
Inventory valuation adjustment |
(84 | ) | (77 | ) | ||||
Gain on disposal of property |
(59 | ) | | |||||
Deferred income tax expense |
68 | 317 | ||||||
Tax benefit from stock-based awards |
(193 | ) | (37 | ) | ||||
Changes in operating assets and liabilities |
||||||||
Accounts receivable trade |
1,997 | (1,309 | ) | |||||
Accounts receivable other |
(502 | ) | (215 | ) | ||||
Inventories |
(1,750 | ) | (517 | ) | ||||
Prepaid expenses and other current assets |
363 | 493 | ||||||
Accounts payable |
1,422 | 1,645 | ||||||
Accrued liabilities |
(708 | ) | (151 | ) | ||||
Net cash provided by operating activities |
6,518 | 6,426 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||
Additions to property, plant and equipment |
(2,155 | ) | (239 | ) | ||||
Proceeds from sale of property |
59 | | ||||||
Change in restricted cash |
189 | 111 | ||||||
Net cash used in investing activities |
(1,907 | ) | (128 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||
Payments under revolver credit agreement |
(3,000 | ) | | |||||
Principal payments on borrowings on term loan |
(2,000 | ) | (1,375 | ) | ||||
Proceeds from exercise of stock options |
200 | | ||||||
Tax benefit from stock-based awards |
193 | 37 | ||||||
Payment of dividends |
(226 | ) | (222 | ) | ||||
Net cash used in financing activities |
(4,833 | ) | (1,560 | ) | ||||
EFFECT OF EXCHANGE RATE CHANGES ON CASH |
229 | 82 | ||||||
NET INCREASE IN CASH AND CASH EQUIVALENTS |
7 | 4,820 | ||||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD |
4,728 | 7,174 | ||||||
CASH AND CASH EQUIVALENTS AT END OF PERIOD |
$ | 4,735 | $ | 11,994 | ||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
||||||||
Cash paid for interest |
$ | 634 | $ | 536 | ||||
Cash paid for income taxes |
$ | 355 | $ | 271 |
See notes
to condensed consolidated financial statements.
5
Table of Contents
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(1) Basis of Presentation.
The (a) consolidated balance sheet as of July 31, 2010, which has
been derived from audited consolidated financial statements, and (b) the unaudited condensed
consolidated financial statements included herein have been prepared pursuant to the rules and
regulations of the Securities and Exchange Commission for interim reporting. As permitted under
those requirements, certain footnotes or other financial information that are normally required by
generally accepted accounting principles in the United States of America (GAAP) have been
condensed or omitted. The Company believes that the disclosures made are adequate to make the
information not misleading and in the opinion of management reflect all adjustments, including
those of a normal recurring nature, that are necessary for a fair presentation of financial
position and results of operations for the interim periods presented. The results of operations for
the interim periods are not necessarily indicative of results of operations to be expected for the
full year. The unaudited condensed consolidated financial statements included herein should be read in
conjunction with the consolidated financial statements and notes thereto included in the Companys
Annual Report on Form 10-K for the year ended July 31, 2010.
These condensed consolidated financial statements are prepared using certain estimates by management and
include the accounts of KMG Chemicals, Inc. and its subsidiaries (collectively, the Company). All
significant intercompany balances and transactions have been eliminated in consolidation. Certain
reclassifications have been made to the prior period consolidated financial statements to conform
to the current period presentation.
(2) Acquisition.
On March 29, 2010, the Company acquired certain assets of the electronic chemicals business of
General Chemical Performance Products, LLC (General Chemical). The acquired business included
products similar to the products of the Companys then existing electronic chemicals business. The
purpose of the acquisition was to expand the Companys product line and increase market share.
The purchase included inventory, a 48,000 square foot manufacturing facility in Hollister,
California and certain equipment at General Chemicals Bay Point, California facility. The Company
additionally entered into a manufacturing agreement with General Chemical under which they will
continue to manufacture certain acid products for us at their Bay Point facility, using the
equipment at the facility which was purchased by the Company. The Company paid $26.8 million in
cash for the acquisition which was financed with available cash and borrowings under the Companys
revolving credit facility.
The following table summarizes the consideration paid for the acquired assets and the
preliminary acquisition accounting for the fair value of the assets recognized in the consolidated
balance sheets at the acquisition date (in thousands):
Consideration: |
||||
Cash |
$ | 26,784 | ||
Fair value of identifiable assets acquired: |
||||
Inventory, net of allowance |
$ | 7,604 | ||
Property, plant and equipment |
17,706 | |||
Intangible assets: |
||||
Value of product qualifications |
1,300 | |||
Non-compete agreement |
150 | |||
Total intangible assets |
1,450 | |||
Other |
24 | |||
Total identifiable assets acquired |
$ | 26,784 | ||
6
Table of Contents
The following table sets forth pro forma results for the three months ended October 31, 2009
had the acquisition occurred as of the beginning of fiscal year 2009. The unaudited pro forma
financial information is not necessarily indicative of what our consolidated results of operations
would have been had we completed the acquisition as of the date indicated.
(Unaudited) | ||||
(in thousands, except | ||||
per share data) | ||||
Three months ended | ||||
October 31, 2009 | ||||
Revenues |
$ | 60,197 | ||
Operating income |
8,502 | |||
Net income |
4,934 | |||
Earnings per share basic |
$ | 0.44 |
The Company is consolidating manufacturing for its U.S.-based electronic chemicals at its
Pueblo, CO and Hollister, CA facilities. As a result it is not practicable to determine the
revenue and earnings attributable to the acquired business included in the Companys consolidated
statements of income for the reporting period.
Depreciation included in the pro forma financial information is approximately $230,000 per
month.
(3) Recent Accounting Standards.
The Company has considered all recently issued Financial
Accounting Standards Board accounting standards updates and SEC rules and interpretive releases,
and believes that none of those items could have a material impact on the Companys consolidated
financial statements.
(4) Earnings Per Share. Basic earnings per share have been computed by dividing net income by
the weighted average shares outstanding. Diluted earnings per share have been computed by dividing
net income by the weighted average shares outstanding plus potentially dilutive common shares. The
following table presents information necessary to calculate basic and diluted earnings per share
for periods indicated:
Three Months Ended | ||||||||
October 31, | ||||||||
2010 | 2009 | |||||||
(Amounts in thousands, | ||||||||
except per share data) | ||||||||
Net income |
$ | 3,516 | $ | 4,620 | ||||
Weighted average shares outstanding-basic |
11,299 | 11,144 | ||||||
Dilutive effect of options and stock awards |
161 | 231 | ||||||
Weighted average shares outstanding-diluted |
11,460 | 11,375 | ||||||
Basic earnings per share |
$ | 0.31 | $ | 0.41 | ||||
Diluted earnings per share |
$ | 0.31 | $ | 0.41 | ||||
Outstanding stock based awards are not included in the computation of diluted earnings per
share under the treasury stock method, if including them would be anti-dilutive. There were no
potentially dilutive securities not included in the computation of diluted earnings per share for
the periods ended October 31, 2010 and 2009.
(5) Inventories.
Inventories are summarized in the following table (in thousands):
October 31, | July 31, | |||||||
2010 | 2010 | |||||||
Raw materials and supplies |
$ | 9,407 | $ | 8,578 | ||||
Finished products |
32,063 | 30,942 | ||||||
Less reserve for inventory obsolescence |
(317 | ) | (418 | ) | ||||
Inventories, net |
$ | 41,153 | $ | 39,102 | ||||
7
Table of Contents
(6) Property, Plant and Equipment.
Property, plant and equipment and related accumulated
depreciation and amortization are summarized as follows (in thousands):
October 31, | July 31, | |||||||
2010 | 2010 | |||||||
Land |
$ | 9,868 | $ | 9,428 | ||||
Buildings & improvements |
34,889 | 34,399 | ||||||
Equipment |
41,002 | 40,195 | ||||||
Leasehold improvements |
132 | 132 | ||||||
85,891 | 84,154 | |||||||
Less accumulated depreciation and amortization |
(20,023 | ) | (18,054 | ) | ||||
65,868 | 66,100 | |||||||
Construction-in-progress |
3,947 | 2,545 | ||||||
Property, plant and equipment, net |
$ | 69,815 | $ | 68,645 | ||||
(7) Stock-Based Compensation.
The Company has stock-based incentive plans which are described
in more detail in note 11 to the consolidated financial statements in the Companys Annual Report
on Form 10-K for fiscal year 2010. The Company recognized stock-based compensation costs of
approximately $181,000 and $86,000, respectively, for the three months ended October 31, 2010 and
2009, which are recorded as selling, general and administrative expenses in the consolidated
statements of income.
As of October 31, 2010, the unrecognized compensation costs related to stock-based awards was
approximately $1.1 million, including $32,000 related to outstanding unvested stock options
expected to be recognized over a weighted-average period of 1.8 years and $1.1 million related to
unvested performance and time-based stock awards expected to be recognized over a weighted-average
period of 1.7 years.
A summary of stock option and stock activity is presented below.
Stock Options
A summary of activity associated with the three months ended October 31, 2010 is presented
below.
Weighted- | ||||||||
Average | ||||||||
Shares | Exercise Price | |||||||
Outstanding on August 1, 2010 |
272,000 | 3.98 | ||||||
Granted |
| | ||||||
Exercised |
(50,000 | ) | 4.00 | |||||
Forfeited/Expired |
| | ||||||
Outstanding on October 31, 2010 |
222,000 | 3.98 | ||||||
The following table summarizes information about stock options outstanding at October 31, 2010
based on fully vested (currently exercisable) stock option awards and stock options awards expected
to vest:
Weighted- | ||||||||||||||||
Weighted- | Average | |||||||||||||||
Average | Remaining | Aggregate | ||||||||||||||
Options | Exercise Price | Contractual | Intrinsic Value | |||||||||||||
Outstanding | per Share | Term (years) | (in thousands) (1) | |||||||||||||
Fully vested and currently exercisable |
159,500 | $ | 3.84 | 5.62 | $ | 1,619 | ||||||||||
Expected to vest |
62,500 | $ | 4.34 | 11.81 | 603 | |||||||||||
Total outstanding stock options |
222,000 | $ | 3.98 | 7.37 | $ | 2,222 | ||||||||||
(1) | The aggregate intrinsic value is computed based on the closing price of the Companys stock
on October 29, 2010. |
No options were granted in the first quarter of fiscal years 2011 or 2010
The total intrinsic value of options exercised during the three months ended October 31, 2010
was approximately $546,000. There were no options exercised during the three months ended October
31, 2009.
8
Table of Contents
Performance Shares
On August 1, 2010, there were 197,249 non-vested performance shares outstanding which
reflected the maximum number of shares under the awards. During the three months ended October 31,
2010, there were no performance-based stock awards vested or granted. As of October 31, 2010, the
unvested performance-based stock awards consisted of Series 1 and Series 2 awards granted to
certain executives in fiscal years 2010 and 2009, are summarized below.
Closing Stock | ||||||||||||||||||||||||
Maximum | Price | 3-Year | Expected | |||||||||||||||||||||
Series | Award | (Fair Value) | Measurement | Percentage of | Shares Expected | |||||||||||||||||||
Date of Grant | Award | (Shares) | on Grant Date | Period Ending | Vesting | to Vest | ||||||||||||||||||
Fiscal Year 2010 |
||||||||||||||||||||||||
3/17/2010 |
Series 1 | 63,605 | $ | 15.55 | 07/31/2012 | 65 | % | 41,343 | ||||||||||||||||
3/17/2010 |
Series 2 | 42,402 | $ | 15.55 | 07/31/2012 | 100 | % | 42,402 | ||||||||||||||||
106,007 | 83,745 | |||||||||||||||||||||||
Fiscal Year 2009 |
||||||||||||||||||||||||
12/02/2008 |
Series 1 | 54,745 | $ | 3.19 | 07/31/2011 | 40 | % | 21,898 | ||||||||||||||||
12/02/2008 |
Series 2 | 36,497 | $ | 3.19 | 07/31/2011 | 20 | % | 7,299 | ||||||||||||||||
91,242 | 29,197 | |||||||||||||||||||||||
Total |
197,249 | 112,942 | ||||||||||||||||||||||
Series 1: Vesting for the Series 1 awards are subject to a performance requirement composed of
certain revenue growth objectives and average annual return on invested capital or equity
objectives measured across a three year period. These objectives are measured quarterly using the
Companys budget, actual results and long term projections. For the fiscal year 2010 and 2009
awards the expected percentage of vesting is based on performance through October 31, 2010 and
reflects the percentage of shares projected to vest for the respective awards at the end of their
measurement periods.
Series 2: Vesting for the Series 2 awards are subject to performance requirements pertaining
to the growth rate in the Companys basic earnings per share over a three year period. The
achievement of performance requirements is measured quarterly using the Companys budget, actual
results and long-term projections. For the fiscal year 2010 and 2009 awards the expected percentage
of vesting is based on performance through October 31, 2010 and reflects the percentage of shares
projected to vest for the respective awards at the end of their measurement periods.
Time Based Shares
A summary of activity for time-based stock awards for the three months ended October 31, 2010
is presented below:
Weighted-Average | ||||||||
Grant-Date | ||||||||
Shares | Fair Value | |||||||
Non-vested on August 1, 2010 |
24,070 | $ | 12.66 | |||||
Granted |
| | ||||||
Vested |
(6,580 | ) | 13.29 | |||||
Forfeited |
| | ||||||
Non-vested on October 31, 2010 |
17,490 | 12.43 | ||||||
The total fair value of shares vested during the three months ended October 31, 2010 and 2009
was approximately $87,500 and $28,000, respectively.
9
Table of Contents
(8) Intangible Assets.
Intangible assets are summarized as follows (in thousands):
October 31, 2010 | ||||||||||||
Original | Accumulated | Carrying | ||||||||||
Cost | Amortization | Amount | ||||||||||
Intangible assets subject to amortization: (range of useful life): |
||||||||||||
Creosote supply contract (10 years) |
$ | 4,000 | $ | (3,756 | ) | $ | 244 | |||||
Animal health trademarks (4-5 years) |
364 | (361 | ) | 3 | ||||||||
Animal health product registrations and other related assets (5-20 years) |
6,165 | (1,752 | ) | 4,413 | ||||||||
Electronic chemicals-related contracts (3-8 years) |
1,164 | (933 | ) | 231 | ||||||||
Electronic chemicals-related trademarks and patents (10-15 years) |
117 | (29 | ) | 88 | ||||||||
Electronic chemicalsvalue of product qualifications (5 years) |
1,300 | (153 | ) | 1,147 | ||||||||
Total intangible assets subject to amortization |
$ | 13,110 | $ | (6,984 | ) | 6,126 | ||||||
Intangible assets not subject to amortization: |
||||||||||||
Creosote product registrations and other creosote related assets |
5,339 | |||||||||||
Penta product registrations |
8,765 | |||||||||||
Total intangible assets not subject to amortization |
14,104 | |||||||||||
Total intangible assets, net |
$ | 20,230 | ||||||||||
July 31, 2010 | ||||||||||||
Original | Accumulated | Carrying | ||||||||||
Cost | Amortization | Amount | ||||||||||
Intangible assets subject to amortization: (range of useful life): |
||||||||||||
Creosote supply contract (10 years) |
$ | 4,000 | $ | (3,689 | ) | $ | 311 | |||||
Animal health trademarks (4-5 years) |
364 | (359 | ) | 5 | ||||||||
Animal health product registrations and other related assets (5-20 years) |
6,165 | (1,667 | ) | 4,498 | ||||||||
Electronic chemicals-related contracts (3-8 years) |
1,164 | (844 | ) | 320 | ||||||||
Electronic chemicals-related trademarks and patents (10-15 years) |
117 | (26 | ) | 91 | ||||||||
Electronic chemicals-value of product qualifications (5 years) |
1,300 | (95 | ) | 1,205 | ||||||||
Total intangible assets subject to amortization |
$ | 13,110 | $ | (6,680 | ) | 6,430 | ||||||
Intangible assets not subject to amortization: |
||||||||||||
Creosote product registrations and other creosote related assets |
5,339 | |||||||||||
Penta product registrations |
8,765 | |||||||||||
Total intangible assets not subject to amortization |
14,104 | |||||||||||
Total intangible assets, net |
$ | 20,534 | ||||||||||
Intangible assets subject to amortization are amortized over their estimated useful lives.
Amortization expense was approximately $304,000 and $243,000 for the three month periods ended
October 31, 2010 and 2009 respectively.
(9) Dividends.
Dividends of approximately $226,000 ($0.02 per share) and $222,000 ($0.02 per
share) were declared and paid in the first quarter of fiscal years 2011 and 2010, respectively.
(10) Comprehensive Income.
The Companys other comprehensive income includes foreign currency
translation gains and losses which are recognized as accumulated other comprehensive income (loss)
in the consolidated balance sheets. The following table summarizes total comprehensive income for
the applicable periods (in thousands):
Three Months Ended | ||||||||
October 31, | ||||||||
2010 | 2009 | |||||||
Net income |
$ | 3,516 | $ | 4,620 | ||||
Other comprehensive income: |
||||||||
Net foreign currency translation gain |
1,478 | 1,026 | ||||||
Total comprehensive income |
$ | 4,994 | $ | 5,646 | ||||
10
Table of Contents
(11) Segment Information.
The Company operates four reportable segments organized around its
three product lines: electronic chemicals, industrial wood preserving chemicals and animal health
products.
The Company previously had five reportable segments, Electronic Chemicals North America,
Electronic Chemicals International, penta, creosote and animal health. During the fourth quarter
of fiscal year 2010 the Company re-evaluated the criteria used to determine operating segments, and
concluded that its electronic chemicals product line met the criteria of a single operating
segment. As a result the composition of the Companys reportable segments was revised to reflect a
change from five to four reportable segments, electronic chemicals, penta, creosote and animal
health. Prior year information has been reclassified to conform to the current period
presentation.
Three Months Ended | ||||||||
October 31, | ||||||||
2010 | 2009 | |||||||
(Amounts in thousands) | ||||||||
Sales |
||||||||
Electronic Chemicals |
$ | 36,793 | $ | 23,011 | ||||
Penta |
6,471 | 5,943 | ||||||
Creosote |
17,689 | 19,527 | ||||||
Animal Health |
1,151 | 933 | ||||||
Total sales for reportable segments |
$ | 62,104 | $ | 49,414 | ||||
Depreciation and amortization |
||||||||
Electronic Chemicals |
$ | 1,756 | $ | 896 | ||||
Penta |
145 | 155 | ||||||
Creosote |
73 | 70 | ||||||
Animal Health |
192 | 192 | ||||||
Other general corporate |
74 | 66 | ||||||
Total consolidated depreciation and amortization |
$ | 2,240 | $ | 1,379 | ||||
Segment income (loss) from operations (1) |
||||||||
Electronic Chemicals |
$ | 3,025 | $ | 902 | ||||
Penta |
2,061 | 2,375 | ||||||
Creosote |
1,768 | 6,320 | ||||||
Animal Health |
(397 | ) | (370 | ) | ||||
Total segment income from operations |
$ | 6,457 | $ | 9,227 | ||||
October 31, | July 31, | |||||||
2010 | 2010 | |||||||
Assets |
||||||||
Electronic Chemicals |
$ | 113,834 | $ | 109,367 | ||||
Penta |
20,172 | 20,094 | ||||||
Creosote |
20,591 | 21,731 | ||||||
Animal Health |
14,829 | 15,950 | ||||||
Total assets for reportable segments |
$ | 169,426 | $ | 167,142 | ||||
(1) | Segment income (loss) from operations includes certain allocated corporate overhead expenses.
During the first quarter of fiscal year 2011, the Company changed the method it uses to
allocate those costs to its reportable segments which is based on segment net sales. As a
result prior year amounts have been reclassified to reflect the current year method. The
total corporate overhead expense allocated to segment income (loss) for the three months ended
October 31, 2010 and 2009 was $1.8 million and $1.7 million, respectively. |
11
Table of Contents
A reconciliation of total segment information to consolidated amounts is as follows:
October 31, | July 31, | |||||||
2010 | 2010 | |||||||
(Amounts in thousands) | ||||||||
Assets: |
||||||||
Total assets for reportable segments |
$ | 169,426 | $ | 167,142 | ||||
Total assets for discontinued operations (1) |
714 | 739 | ||||||
Cash and cash equivalents |
2,182 | 3,073 | ||||||
Prepaid and other current assets |
2,166 | 2,174 | ||||||
Other |
3,177 | 2,893 | ||||||
Total assets |
$ | 177,665 | $ | 176,021 | ||||
Three Months Ended | ||||||||
October 31, | ||||||||
2010 | 2009 | |||||||
Sales: |
||||||||
Total sales for reportable segments |
$ | 62,104 | $ | 49,414 | ||||
Net sales |
$ | 62,104 | $ | 49,414 | ||||
Segment income from operations: |
||||||||
Total segment income from operations (2) |
$ | 6,457 | $ | 9,227 | ||||
Other corporate expense (2) |
(897 | ) | (1,277 | ) | ||||
Operating income |
5,560 | 7,950 | ||||||
Interest income |
1 | 1 | ||||||
Interest expense |
(595 | ) | (557 | ) | ||||
Other income (expense), net |
51 | (28 | ) | |||||
Income before income taxes |
$ | 5,017 | $ | 7,366 | ||||
(1) | Includes approximately $714,000 and $739,000 as of October 31, 2010 and July 31, 2010,
respectively, of long-term deferred tax assets related to discontinued operations. |
|
(2) | Other corporate expense
represents those expenses associated with the companys
operation as a public entity and includes costs such as board compensation, audit expense and fees related to the listing of our stock. During the first
quarter of fiscal year 2011, the Company changed the method it uses to allocate certain
corporate overhead costs to its reportable segments, and accordingly prior year amounts have
been reclassified to reflect the current year method. |
(12) Long-Term Obligations.
The Companys debt consisted of the following (in thousands):
October 31, | July 31, | |||||||
2010 | 2010 | |||||||
Senior Secured Debt: |
||||||||
Note Purchase Agreement, maturing on December 31, 2014, interest rate of 7.43% |
$ | 20,000 | $ | 20,000 | ||||
Secured Debt: |
||||||||
Term Loan Facility, maturing on December 31, 2012, variable interest rates
based on LIBOR plus 2.00% (2.26% at October 31, 2010) |
17,333 | 19,333 | ||||||
Revolving Loan Facility, maturing on December 31, 2012, variable interest
rates based on LIBOR plus 2.00% (2.26% at October 31, 2010) |
17,000 | 20,000 | ||||||
Total debt |
54,333 | 59,333 | ||||||
Current portion of long-term debt |
(8,000 | ) | (8,000 | ) | ||||
Long-term debt, net of current portion |
$ | 46,333 | $ | 51,333 | ||||
To finance the acquisition of the electronic chemicals business from Air Products in December
2007, the Company entered into a credit agreement and a note purchase agreement. The credit
facility included a revolving loan facility of $35.0 million and a term loan facility of $35.0
million. The Company amended those facilities in March 2010 to increase the amount that may be
borrowed under the revolving loan facility to $50 million. The facility was entered into with
Wachovia Bank, National Association, a subsidiary of Wells Fargo & Co., Bank of America, N.A., The
Prudential Insurance Company of America, and Pruco Life Insurance Company. Advances under the
revolving loan and the term loan mature December 31, 2012. The revolving loan and the term loan
each bear interest at varying rate of LIBOR plus a margin based on our funded debt to earnings
before interest, taxes, depreciation and amortization (EBITDA).
12
Table of Contents
Ratio of Funded Debt to EBITDA | Margin | |||
Equal to or greater than 3.0 to 1.0 |
2.75 | % | ||
Equal to or greater than 2.5 to 1.0, but less than 3.0 to 1.0 |
2.50 | % | ||
Equal to or greater than 2.0 to 1.0, but less than 2.5 to 1.0 |
2.25 | % | ||
Equal to or greater than 1.5 to 1.0, but less than 2.0 to 1.0 |
2.00 | % | ||
Less than 1.5 to 1.0 |
1.75 | % |
As of November 30, 2010, advances under the revolving loan and the term loan bear interest at
LIBOR plus 2.00%. For the first 24 months of the term facility, principal payments were $458,333,
per month and then beginning January 2010 principal payments became $666,667 per month for the
balance of the term prior to maturity.
The purchase of the electronic chemicals assets from General Chemical on March 29, 2010 was
funded with available cash and borrowings under the revolving loan. At October 31, 2010, the amount
outstanding on the revolving loan was $17.0 million and the amount outstanding on the term loan was
$17.3 million.
In fiscal year 2008 the Company also entered into a $20.0 million note purchase agreement with
the Prudential Insurance Company of America. Advances under the note purchase agreement mature
December 31, 2014, and bear interest at 7.43% per annum. Principal is payable at maturity. At
October 31, 2010, $20.0 million was outstanding under the note purchase agreement.
Loans under the amended and restated credit facility and the note purchase agreement are
secured by the Companys assets, including inventory, accounts receivable, equipment, intangible
assets, and real property. The credit facility and the note purchase agreement have restrictive
covenants, including that the Company must maintain a fixed charge coverage ratio of 1.5 to 1.0,
and maintain a ratio of funded debt to EBITDA of 3.0 to 1.0. The Company is also obligated to
maintain a debt to capitalization ratio of not more than 50%. For purposes of calculating these
financial covenant ratios, we use a pro forma EBITDA. On October 31, 2010, the Company was in
compliance with all of its debt covenants.
(13) Income Taxes.
Income tax expense for the interim periods was computed using the effective
tax rate estimated to be applicable for the full fiscal year. The effective tax rate for the first
quarter of fiscal year 2011 was 29.9%, which included the effect of an adjustment recognized during
the period of $410,000 for the reversal of a portion of the valuation allowance related to a
foreign subsidiary.
13
Table of Contents
ITEM 2. | MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
We manufacture, formulate and distribute specialty chemicals globally. We operate businesses
engaged in electronic chemicals, industrial wood preservation chemicals and animal health products.
Our electronic chemicals are used in the manufacturing of semiconductors. Our wood preserving
chemicals, pentachlorophenol (penta) and creosote, are used by our industrial customers primarily
to extend the useful life of utility poles and railroad crossties. Our animal health products
include biotech feed additives, farm and ranch hygiene products and pesticide products used on
cattle, other livestock and poultry to protect the animals from flies and other pests.
Results of Operations
Three Month Period Ended October 31, 2010 compared with Three Month Period Ended October 31, 2009
Segment Data
Segment data is presented for our four reportable segments for the three month periods ended
October 31, 2010 and 2009. The segment data should be read in
conjunction with our condensed consolidated
financial statements and related notes thereto included elsewhere in this report. We previously
had five reportable segments, Electronic Chemicals-North America, Electronic
Chemicals-International, and segments for penta, creosote and animal health. During the fourth
quarter of fiscal year 2010 we re-evaluated the criteria used to determine operating segments, and
we concluded that our electronic chemicals product line met the criteria of a single operating
segment. As a result our reportable segments were revised to reflect a change from five to four
reportable segments, electronic chemicals, penta, creosote and animal health. Prior year
information has been reclassified to conform to the current period presentation.
Three Months Ended | ||||||||
October 31, | ||||||||
2010 | 2009 | |||||||
(Amounts in thousands) | ||||||||
Sales |
||||||||
Electronic Chemicals |
$ | 36,793 | $ | 23,011 | ||||
Penta |
6,471 | 5,943 | ||||||
Creosote |
17,689 | 19,527 | ||||||
Animal Health |
1,151 | 933 | ||||||
Net sales |
$ | 62,104 | $ | 49,414 | ||||
Net Sales
Net sales increased $12.7 million, or 25.7%, to $62.1 million in the first quarter of fiscal
year 2011 as compared with $49.4 million for the same period of the prior year.
In the first quarter of fiscal year 2011, the electronic chemicals segment had net sales of
$36.8 million, an increase of $13.8 million, or 59.9%, as compared to the prior year period. We had increased sales from our March 2010
acquisition of General Chemicals electronic chemicals business, and demand recovered in the
segment from the effect of the economic downturn in the semiconductor industry. Approximately 95%
of the increase was attributable to net sales in North America.
Net sales of penta products increased $528,000, or 8.9%, to $6.5 million in the first quarter
of fiscal year 2011 as compared to the prior year period. The increase in sales for the three month
period was due to higher volume. We benefited from an incremental improvement in purchases of
treated poles by utility companies.
Creosote net sales decreased in the first quarter of fiscal year 2011, as compared with the
prior year period, by $1.8 million, or 9.4%, to $17.7 million. The decrease resulted from lower
average prices, partially offset by an increase in volume in the first quarter of fiscal year 2011
as compared with the prior year period. Demand by railroads for crossties treated with creosote eased in 2010 from the high levels of previous years. While
crosstie purchases for the 12 month period ending October 31, 2010 averaged 19 million ties, production rates of
treated crossties averaged just 16 million ties. Offsetting this downward trend was a shift in the market to a crosstie
treatment that did not include blending with petroleum, thereby increasing the demand for creosote. Average pricing
during the quarter declined with the consolidation of our wood treating customer base coupled with the threat of
off-shore material finding its way into the U.S. market. We successfully completed a significant supply contract with
our largest creosote customer and anticipate pricing will remain relatively flat with first quarter levels through
fiscal year 2011. We expect sales volumes to increase in the second half of the fiscal year as rail tie production
rates more closely approximate tie purchases.
14
Table of Contents
Net sales of animal health pesticides increased by $218,000, or 23.4%, to $1.2 million in the
first quarter of fiscal year 2011 as compared with the prior year period. The increase was primarily driven by improvement in
demand for pest control in the U.S. feed animal sector, but farm and livestock customers continue
to be impacted by the effect of high costs for feed, fuel, and fertilizer. The U.S. Environmental
Protection Agency (EPA) failed to timely review residue studies for Rabon products
(tetrachlorvinphos) that we had submitted several years ago, and failed to establish permanent
residue tolerances based on those studies. Although we are working to have EPA re-establish
appropriate tolerances, pending a successful conclusion of that effort, sales of our Rabon products
in the U.S. may be adversely affected. Sales of our Rabon products in the U.S. constituted
approximately 2% of our fiscal year 2010 consolidated net sales. Seasonal usage of animal health
pesticides is dependent on varying seasonal patterns, weather conditions and weather-related
pressure from pests, as well as customer marketing programs and requirements. Our revenue from the
animal health pesticides segment is seasonal and weighted to the third and fourth quarters.
Revenues from products subject to significant seasonal variations represented 5.0% of our fiscal
year 2010 revenues.
Gross Profit
Gross profit decreased by $1.0 million, or 5.6%, to $17.4 million in the first quarter of
fiscal year 2011 from $18.4 million in the same quarter the prior year. Gross profit as a
percentage of sales decreased to 28.0% in the first quarter of fiscal year 2011 from 37.2% in the
first quarter of fiscal year 2010.
The decline in aggregate gross profit was primarily from our creosote segment, but offset in
part by improved sales and corresponding gross profit in our electronic chemicals segment. Gross
profits in our two wood preservatives segments decreased in the first quarter of fiscal year 2011
as compared with the prior year period. The majority of the decrease was attributable to our
creosote segment, where we saw increased costs for creosote and a lower average sales price. The decrease in our penta segment was due to higher costs of
chlorine and solvent raw materials used to produce our penta products, offset in part by higher
sales as a result of increased volumes. Gross profit in our animal health segment was relatively
flat in the first quarter as compared with the prior year.
Other companies may include certain of the costs that we record in cost of sales as
distribution expenses or selling, general and administrative expenses, and may include certain of
the costs that we record in distribution expenses or selling, general and administrative expenses
as a component of cost of sales, resulting in a lack of comparability between our gross profit and
that reported by other companies.
Distribution Expenses
Distribution expenses are presented as a line item separate from our selling, general and
administrative expenses in the consolidated statements of income. Prior year information has been
reclassified to conform to this presentation.
Distribution expenses increased by $1.4 million, or 26.9%, to $6.4 million in the first
quarter of fiscal year 2011 as compared with $5.0 million in the prior year period. The increase
was primarily due to increased freight expense of $958,000 for our electronic chemicals
business, approximately half of which was related to the business acquired from General Chemical. For
electronic chemicals, distribution expense was 14.4% of net sales in the first quarter versus 18.1%
in the prior year. The decline in distribution expense as a percent
of sales was due to the efficiency measures implemented in
conjunction with the previous acquisitions integration. Our two wood preservatives segments and our animal health segments had an
aggregate increase of approximately $200,000 in distribution expenses, mainly because of higher
freight and, because we cleaned more cars, railcar cleaning expenses. Distribution expenses in the aggregate were approximately
10.3% of net sales in the first quarter of fiscal year 2011 and 10.2% in the prior year period.
Selling, General and Administrative Expenses
Selling, general, and administrative expenses were $5.4 million in the first quarter of each
of fiscal year 2011 and fiscal year 2010. Those expenses were 8.8% of sales in the first quarter
of fiscal year 2011 and 11.0% of sales in the first quarter of the prior year.
Selling, general and administrative expenses associated with our electronic chemicals segment
increased approximately $390,000, to $2.8 million, in the first quarter of fiscal year 2011 as
compared to $2.4 million for the first quarter of fiscal year 2010. The current period included
$176,000 of integration costs in connection with the electronic chemicals business we acquired from
General Chemical in March 2010. Selling, general and administrative expenses related to each of
our other segments were relatively flat.
15
Table of Contents
Interest Expense
Interest expense was $595,000 in the first quarter of fiscal year 2011 as compared with
$557,000, in the same period of fiscal year 2009. The increase was due to an increase in our
revolving loan facility balance to finance the acquisition of the electronic chemicals business of
General Chemical in March 2010.
Income Taxes
Our effective tax rate was 29.9% and 37.3% in the first quarter of fiscal years 2011 and 2010,
respectively. The current year period income tax expense was net of a discrete period adjustment of
$410,000 reflecting the reversal of a portion of the valuation allowance related to a foreign
subsidiary.
Liquidity and Capital Resources
Cash Flows
Net cash provided by operating activities was $6.5 million for the first three months of
fiscal year 2011 as compared to $6.4 million for the comparable period in 2010. Net income adjusted
for depreciation and amortization increased cash to $5.8 million in the first three months of
fiscal year 2011. Changes in operating assets and liabilities included a decrease of $2.0 million
in accounts receivable and an increase in accounts payable of $1.4 million, both of which had a
favorable impact on cash. The decrease in accounts receivable was primarily due to the seasonality
of the animal health business. Most of our animal health sales occur in the second half of our
fiscal year. The increase in accounts payable was primarily related to increased activity related
to our recently acquired electronic chemicals business. Cash was unfavorably impacted by an
increase in inventories of $1.8 million due to higher inventories resulting from the newly acquired
electronic chemicals business.
Net cash used in investing activities in the first three months of fiscal 2011 was $1.9
million as compared with $128,000 in the prior year period. We made additions to property, plant
and equipment of $2.2 million during the first quarter of fiscal year 2011 as compared to $239,000
in the first quarter of fiscal year 2010. In the first quarter of fiscal year 2011 we spent
approximately $1.2 million in connection with our ongoing expansion project at our Hollister, CA
facility. We additionally made approximately $435,000 of capital expenditures at our Pueblo, CO
facility for equipment purchases and upgrades, some of which are in connection with our ongoing
consolidation of our U.S. based electronic chemicals manufacturing. The remaining capital
expenditures were for normal equipment and system upgrades and purchases across our different
locations.
Net cash used in financing activities was $4.8 million in the first three months of fiscal
year 2011 as compared to $1.6 million in the comparable prior year period. In the first three
months of fiscal year 2011, we made principal payments of $2.0 million on the term loan
indebtedness we incurred when we purchased the electronic chemicals business in December 2007. We
additionally made payments of $3.0 million on our revolving credit line in the current period which
reflects amounts borrowed to fund our March 2010 acquisition. In the first three months of fiscal
year 2010, we made principal payments of $1.4 million on the term loan indebtedness. We paid
dividends of $226,000 and $222,000 in the first three months of fiscal years 2011 and 2010,
respectively. It is our policy to pay dividends from available cash after taking into consideration
our profitability, capital requirements, financial condition, growth, business opportunities and
other factors which our board of directors may deem relevant.
Working Capital
We have a revolving line of credit under an amended and restated credit agreement. At October
31, 2010, we had $17.0 million outstanding under that revolving facility, and our net borrowing
base availability was $17.1 million. Management believes that our current credit facility, combined
with cash flows from operations, will adequately provide for our working capital needs for current
operations for the next twelve months.
16
Table of Contents
Long Term Obligations
To finance the acquisition of the electronic chemicals business in December 2007, we entered
into an amended and restated credit agreement and a note purchase agreement with Wachovia Bank,
National Association, a subsidiary of Wells Fargo & Co., Bank of America, N.A., The Prudential
Insurance Company of America, and Pruco Life Insurance Company. The new credit facility included a
revolving loan facility of $35.0 million and a term loan facility of $35.0 million. We amended
those facilities in March 2010 to increase the amount that may be borrowed under the revolving loan facility to $50.0 million.
Advances under the revolving loan and the term loan mature December 31, 2012. They each bear
interest at varying rate of LIBOR plus a margin based on our funded debt to EBITDA, as described
below.
Ratio of Funded Debt to EBITDA | Margin | |||
Equal to or greater than 3.0 to 1.0 |
2.75 | % | ||
Equal to or greater than 2.5 to 1.0, but less than 3.0 to 1.0 |
2.50 | % | ||
Equal to or greater than 2.0 to 1.0, but less than 2.5 to 1.0 |
2.25 | % | ||
Equal to or greater than 1.5 to 1.0, but less than 2.0 to 1.0 |
2.00 | % | ||
Less than 1.5 to 1.0 |
1.75 | % |
As of November 30, 2010, advances bear interest at LIBOR plus 2.00%. For the first 24 months
of the term facility, principal payments were $458,333 per month, and then beginning January 2010
principal payments became $666,667 per month for the balance of the term prior to maturity. The
purchase of the electronic chemicals assets from General Chemical on March 29, 2010 was funded with
available cash and borrowings under the revolving loan. At October 31, 2010, $17.0 million was
outstanding on the revolving facility and $17.3 million was outstanding on the term loan.
The financing for the acquisition of the electronic chemicals business in fiscal year 2008
included a $20.0 million note purchase agreement we entered into with the Prudential Insurance
Company of America. Advances under the note purchase agreement mature December 31, 2014, and bear
interest at 7.43% per annum. Principal is payable at maturity. At October 31, 2010, $20.0 million
was outstanding under the note purchase agreement.
Loans under the amended and restated credit facility and the note purchase agreement are
secured by our assets, including inventory, accounts receivable, equipment, intangible assets and
real property. The credit facility and the note purchase agreement have restrictive covenants,
including that we must maintain a fixed charge coverage ratio of 1.5 to 1.0, and a ratio of funded
debt to EBITDA of 3.0 to 1.0. We are also obligated to maintain a debt to capitalization ratio of
not more than 50%. For purposes of calculating these financial covenant ratios, we use a pro forma
EBITDA. On October 31, 2010, we were in compliance with all of our debt covenants.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements, such as financing or unconsolidated variable
interest entities.
Recent Accounting Standards
We have considered all recently issued Financial Accounting Standards Board accounting
standards updates and SEC rules and interpretive releases, and believe that none of those items
could have a material impact on our consolidated financial statements.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements are prepared in conformity with accounting principles
generally accepted in the United States of America. The preparation of these condensed consolidated financial
statements requires the use of estimates, judgments, and assumptions that affect the reported
amounts of assets and liabilities at the date of the condensed consolidated financial statements and the
reported amounts of revenues and expenses during the periods presented. There were no significant
changes in our critical accounting policies as described in our Annual Report on Form 10-K for the
fiscal year ended July 31, 2010.
Disclosure Regarding Forward Looking Statements
We are including the following discussion to inform our existing and potential security
holders generally of some of the risks and uncertainties that can affect us and to take advantage
of the safe harbor protection for forward-looking statements that applicable federal securities
law affords. From time to time, our management or persons acting on our behalf make forward-looking
statements to inform existing and potential security holders about our company. These
forward-looking statements include information about possible or assumed future results of our
operations. All statements, other than statements of historical facts, included or incorporated by
reference in this report that address activities, events or developments that we expect or
anticipate may occur in the future, including such things as future capital expenditures, business
strategy, competitive strengths, goals, growth of our business and operations, plans and references
to future successes may be considered forward-looking statements. Also, when we use words such as
anticipate, believe, estimate, intend, plan, project, forecast, may, should,
budget, goal, expect, probably or similar expressions, we are making forward-looking
statements. Many risks and uncertainties may impact the matters addressed in these forward-looking
statements. Our forward-looking statements speak only as of the date made and we will not update
forward-looking statements unless the securities laws require us to do so.
17
Table of Contents
Some of the key factors which could cause our future financial results and performance to vary
from those expected include:
| the loss of primary customers; |
| our ability to implement productivity improvements, cost reduction initiatives or
facilities expansions; |
| market developments affecting, and other changes in, the demand for our products and the
introduction of new competing products; |
| availability or increases in the price of our primary raw materials or active
ingredients; |
| the timing of planned capital expenditures; |
| our ability to identify, develop or acquire, and market additional product lines and
businesses necessary to implement our business strategy and our ability to finance such
acquisitions and development; |
| the condition of the capital markets generally, which will be affected by interest rates,
foreign currency fluctuations and general economic conditions; |
| cost and other effects of legal and administrative proceedings, settlements,
investigations and claims, including environmental liabilities which may not be covered by
indemnity or insurance; |
| the effects of weather, earthquakes, other natural disasters and terrorist attacks; |
| the ability to obtain registration and re-registration of our products under applicable
law; |
| the political and economic climate in the foreign or domestic jurisdictions in which we
conduct business; and |
| other United States or foreign regulatory or legislative developments which affect the
demand for our products generally or increase the environmental compliance cost for our
products or impose liabilities on the manufacturers and distributors of such products. |
The information contained in this report, including the information set forth under the
heading Risk Factors, identifies additional factors that could cause our results or performance
to differ materially from those we express in our forward-looking statements. Although we believe
that the assumptions underlying our forward-looking statements are reasonable, any of these
assumptions and, therefore, the forward-looking statements based on these assumptions, could
themselves prove to be inaccurate. In light of the significant uncertainties inherent in the
forward-looking statements which are included in this report and the exhibits and other documents
incorporated herein by reference, our inclusion of this information is not a representation by us
or any other person that our objectives and plans will be achieved.
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK |
We are exposed to certain market risks in the ordinary course of our business, arising
primarily from changes in interest rates and to a lesser extent foreign currency exchange rate
fluctuations. Generally we do not utilize derivative financial instruments or hedging transactions
to manage that risk.
Interest Rate Sensitivity
As of October 31, 2010 our fixed rate debt consisted of $20.0 million of term notes with an
interest rate of 7.43%, maturing on December 31, 2014.
18
Table of Contents
As of October 31, 2010 our variable rate debt consisted of a credit facility with an interest
rate of LIBOR plus 2.00%, maturing on December 31, 2012. On October 31, 2010, we had $17.0 million
borrowed on our $50.0 million revolving credit line under that facility, and $17.3 million borrowed
on a term loan under that same facility. Principal payments on the term loan were $458,333 per
month for the first two years of the term facility and now are $666,667 per month for the remaining
term of the facility.
Based on the outstanding balance of the term loan and LIBOR rate as of October 31, 2010, a
1.0% change in the interest rate would result in a change of approximately $273,000 in interest
expense for the next twelve months.
Foreign Currency Exchange Rate Sensitivity
We are exposed to fluctuations in foreign currency exchange rates from our electronic
chemicals international segment. Our international operations are centered in Europe and use a
different functional currency, the Euro, than the U.S. Dollar which is our consolidated reporting
currency. Currency translation gains and losses result from the process of translating the
segments financial statements from its functional currency into our reporting currency. Currency
translation gains and losses have no impact on the consolidated statements of income and are
recorded as accumulated other comprehensive income (loss) within stockholders equity in our
consolidated balance sheets. Assets and liabilities have been translated using exchange rates in
effect at the balance sheet dates. Revenues and expenses have been translated using the average
exchange rates during the period.
During the three months ended October 31, 2010, we recognized foreign currency translation
gains of $1.5 million as accumulated other comprehensive income in the consolidated balance sheets.
At October 31, 2010, the cumulative foreign currency translation loss reflected in accumulated
other comprehensive loss was $1.9 million.
Additionally we have limited exposure to certain transactions denominated in a currency other
than the functional currency in our Italy operations. Accordingly, we recognize exchange gains or
losses in our consolidated statement of operations from these transactions. We believe the impact
of changes in foreign currency exchange rates does not have a material effect on our results of
operations or cash flows.
ITEM 4. | CONTROLS AND PROCEDURES |
The term disclosure controls and procedures is defined in Rules 13a-15(e) and 15d-15(e) of
the Securities Exchange Act of 1934. This term refers to the controls and procedures of a company
that are designed to ensure that information required to be disclosed by a company in the reports
that it files or submits under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified by the Securities and Exchange Commission. Our management,
including our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness
of our disclosure controls and procedures as of the end of the period covered by this report. Based
upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that
our disclosure controls and procedures were effective as of the end of the period covered by this
report.
There were no changes to our internal control over financial reporting during the quarterly
period covered by this Report on Form 10-Q that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.
PART II OTHER INFORMATION
ITEM 1. | LEGAL PROCEEDINGS |
We have previously reported that litigation was filed in 2007 against us in Superior Court,
Fulton County, Georgia (Atlanta) styled John Bailey, et al vs Cleveland G. Meredith et al. The case
was consolidated in the Superior Court with other plaintiffs cases as Thompson et al vs Meredith
et al. The plaintiffs are persons living near the wood treating facility of one of our customers.
The plaintiffs complain that emissions from the wood treating facility have caused harm to their
property and person, and claim that we are also responsible because we sold wood treating chemicals
to the facility. In fiscal year 2010, the court granted our motion for summary judgment and
dismissed us from the case, but the plaintiffs have appealed. Given the inherent uncertainties of
litigation, the ultimate outcome cannot be predicted at this time, nor can the amount of any
potential loss be reasonably estimated.
We discontinued the operation of our agricultural herbicide product line, referred to as MSMA,
but in connection with that product line we were a member of the MSMA task force. An entity related
to the MSMA task force, Arsonate Herbicide Products, Limited) (AHP), was sued by Albaugh, Inc. in
2007 claiming that AHP overbilled it for certain task force expenses. Although Albaugh Inc. had
agreed to reimburse AHP for certain task force expenses for MSMA studies and registration support
costs, it claims that it was
overbilled for many years by at least $900,000. The case was tried in October 2009 in the U.S.
District Court for the So. District of Iowa, and styled as Albaugh, Inc. vs. Arsonate Herbicide
Products, Limited. The court has not yet rendered a ruling on the case. Given the inherent
uncertainties of litigation, the ultimate outcome cannot be predicted at this time, nor can the
amount of any potential loss be reasonably estimated.
19
Table of Contents
We have previously reported that a lawsuit was filed against our subsidiary, KMG de Mexico,
relating to the title to the land on which our facility in Matamoros is located. The plaintiffs
claim that their title to the land was superior to the person from whom our subsidiary bought the
land. The lawsuit was initially filed in 1998 Matamoros, Mexico under Adolfo Cazares Rosas, et al
vs. KMG de Mexico and Guillermo Villarreal. The plaintiffs are seeking to have our purchase
overturned and to recover the land or its value. In January 2008, the case was sent by the appeals
court back to the lower court to obtain additional factual information, and in April 20, 2009 the
plaintiffs were required to re-file the case in the First Civil Court in Matamoros, Tamaulipas,
Mexico as Adolfo Cazares, Luis Escudero and Juan Cue vs. KMG de Mexico and Guillermo Villarreal.
The ultimate outcome of this litigation cannot be determined at this time, nor can the amount of
any potential loss be reasonably estimated.
We are periodically a party to other legal proceedings and claims that arise in the ordinary
course of business. We do not believe that the outcome of any of those matters will have a material
adverse effect on our business, financial condition and operating results.
ITEM 1A. | RISK FACTORS |
There have been no material changes to the risk factors contained in our Annual Report on Form
10-K for the fiscal year ended July 31, 2010.
ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
Not applicable.
ITEM 3. | DEFAULTS UPON SENIOR SECURITIES |
Not applicable.
ITEM 4. | REMOVED AND RESERVED |
ITEM 5. | OTHER INFORMATION |
The Nominating and Corporate Governance Committee will consider recommendations for directors
made by shareholders for fiscal year 2012, if such recommendations are received in writing,
addressed to the chair of the committee, Mr. Urbanowski, in care of the Company, at 9555 W. Sam
Houston Parkway S., Suite 600, Houston, Texas 77099 by July 2, 2011.
ITEM 6. | EXHIBITS |
The financial statements are filed as part of this report in Part 1, Item 1. The following
documents are filed as exhibits. Documents marked with an asterisk (*) are management contracts or
compensatory plans, and portions of documents marked with a dagger () have been granted
confidential treatment.
31.1 | Certificates under Section 302 the Sarbanes-Oxley Act of 2002 of the Chief Executive Officer. |
|||
31.2 | Certificates under Section 302 the Sarbanes-Oxley Act of 2002 of the Chief Financial Officer. |
|||
32.1 | Certificates under Section 906 of the Sarbanes-Oxley Act of 2002 of the Chief Executive Officer. |
|||
32.2 | Certificates under Section 906 of the Sarbanes-Oxley Act of 2002 of the Chief Financial Officer. |
20
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
KMG Chemicals, Inc. | ||||||
By:
|
/s/ J. Neal Butler | Date: December 10, 2010 | ||||
President and Chief Executive Officer | ||||||
By:
|
/s/ John V. Sobchak | Date: December 10, 2010 | ||||
Vice President and Chief Financial Officer |
21